 |
|
|
|
|
Abstract
Introduction
Monoclonal antibodies (MAbs) are very hot commodities in today' s
pharmaceutical marketplace, and in recent years, the growth in the number of
MAbs under development has far outpaced the growth of other types of drugs.
With expert insight from our Decision Resources analysts, we look at
approximately 70 MAbs in latestage development, identify promising MAbs, and
discuss four developing trends in MAb markets.
Get the Answers You Need to Shape Your Strategy
- Monoclonal antibodies are one of the fastest growing segments of the
pharmaceutical industry. Will the intense competition in this market lead
to saturation in some segments? Which classes could get crowded if new MAbs in
development successfully enter the market?
- MAbs are highly sought after by the pharmaceutical industry to fi ll
sparse pipelines with new biologics. Which companies are looking to ramp up
their MAb production? Who will be the key players in this arena going
forward?
- MAb markets are becoming complex, and companies with emerging MAbs need to
carefully consider how best to position their products. Which factors will
be the most important to ensuring market success for new MAbs? What strategies
are companies pursuing?
Scope
- A review of the evolving biologics market: the role of MAbs, sales
fi gures, market leaders.
- MAbs in development in ten different drug classes: their stage of
development and the companies developing them.
- Four interesting trends in MAb markets: developments that are
adding new layers of complexity to the MAb landscape, trends to be carefully
considered when entering or competing in today' s evolving MAb markets,
implications for stakeholders.
- Expert insight from Decision Resources analysts: comparison of the
relative merits of MAbs now in development, by the following analysts:
- Madhuri Borde, Ph.D., analyst, Immune and Infl ammatory Disorders
- Sylvia Eash, Ph.D., analyst, Infectious Disease
- Clair Gricks, Ph.D., analyst, Onkos
- Neil Grubert, M.A., director of pricing and reimbursement, Spectrum,
Pharmacoeconomics, Pricing, and Reimbursement
- Bethany A. Kiernan, Ph.D., analyst, Cognos
- Joanna Kim, M.Ed., analyst, Immune and Infl ammatory Disorders
- Nitasha Manchanda, Ph.D., analyst, Cognos
- Jennifer Moniz Carpenter, M.B.A., program manager, Spectrum, Therapy
Markets and Emerging Technologies
- Mohamed Muhsin, M.Sc., analyst, Onkos
- Alice von Loesecke, Ph.D., senior director, New Products
|
|
|
|
|
|
View Cart
